ClinicalTrials.gg

Liver Cirrhosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,302 studies for Liver Cirrhosis across more than 10 countries. 340 are recruiting or about to start. 792 of them are mainly about Liver Cirrhosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Liver Cirrhosis, Biliary: 1,545 studies, 397 open.

ClinicalTrials.gov finds 2,746 studies for Liver Cirrhosis. How that becomes 1,302 here

This page counts the studies the registry files under Liver Cirrhosis, and those it files under no condition that list Liver Cirrhosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 2,746Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −243Filed under a narrower condition, counted on its own pageLiver Cirrhosis, Biliary 205 · Liver Cirrhosis, Alcoholic 38
  3. −11List Liver Cirrhosis as a condition, but the registry did not file them under itMost often written as “Liver Cirrhosis, Experimental” (2), “Sarcopenia in Liver Cirrhosis” (2), and “Liver Cirrhosis Due to Virus C Chronic Hepatitis” (1). The registry filed them under other conditions only, most often Fibrosis (6) and Sarcopenia (3).
  4. −1,190Match it another way130 name it in the title, 5 in a keyword, and 1,055 by a synonym or other text the search reads.
  5. 1,302The count on this page30 of them list Liver Cirrhosis in their own words; the registry filed them under no condition.

Status

Completed
524
Status unknown
276
Recruiting
207
Not yet recruiting
116
Terminated
69
Active, not recruiting
61

Phase

Phase 2
168
Phase 3
98
Phase 1
95
Phase 4
93
Early Phase 1
8

Where

United States
231
China
215
France
95
India
85
Germany
82
Italy
78

Who develops what

Add Liver Cirrhosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 4 companies, 4 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare AstraZeneca, Boehringer Ingelheim and GNI Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TerlipressinRecent, limited
Evidence
  • NCT06256432 · Noorik Biopharmaceuticals AG · Phase 2 · live · comparator · “Terlipressin” · registered Feb 2024
Keenova Therapeutics plc50% of its industry studiesUS: Keenova Therapeutics plc (FDA 2022)11 study
AlbuminsRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06355479 · Healthgen Biotechnology Corp. · Phase 3 · comparator · “Plasbumin®-20” · registered Mar 2024
Grifols60% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 7 Jul 2027 est.AZD2389 · AstraZeneca · Phase 2 main aimNCT07610837 Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis — primary endpoint: Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24 · 104 enrolled
  • 5 Aug 2027 est.BI 3802876 · Boehringer Ingelheim · Phase 2 main aimNCT07325526 A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) — primary endpoint: Occurrence of any Adverse Events (AEs) · 30 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Liver Cirrhosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Statins 4 open · Proton pump inhibitors (PPIs) 3 open · Factor Xa inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 2 open · SGLT2 inhibitors 1 open

Coming up

110studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 207 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 65 (31%) stop at 75 or younger. 12 (6%) take children under 18. 1 (<1%) are for women only and 1 (<1%) for men only; 25 (12%) take healthy volunteers.

Recruiting studies that take each age, of 207
AgeWomenMen
1010 (5%)10 (5%)
18187 (90%)187 (90%)
30197 (95%)197 (95%)
40198 (96%)198 (96%)
50201 (97%)201 (97%)
65198 (96%)198 (96%)
75174 (84%)174 (84%)
85120 (58%)119 (57%)

Across all 1,302 studies, recruiting or not: 42% stop at 75 or younger and 16% at 65; 10% take children; <1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Liver Cirrhosis studies take

Of 55 phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo2–29 · 32 studies——
Phase 227 mo19–56 · 55 studies24 mo16–27 · 28 studies—
Phase 366 mo25–82 · 25 studies——
Phase 442 mo13–… · 36 studies——
Interventional, no phase32 mo17–54 · 216 studies—36 mo19–73 · 207 studies
Observational47 mo18–71 · 247 studies—47 mo19–71 · 231 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Stopped2

Studies

Recruiting first, then most recently updated. Showing 50 of 1,302. Browse all 1,302 → or search them.